Yi Xia (0000-0001-5863-7272)

Personal information

No personal information available

Biography

Dr. Yi Xia received her B.S. and Ph.D degree in chemistry from Wuhan University. Then she undertook her postdoctoral research in medicinal chemistry at the Interdisciplinary Center on Nanoscience in Marseille (CINaM) in France. From 2012-2014, she worked at Vancouver Prostate Centre in Canada and pursued her research in cancer biology. Since September 2014, Dr. XIA has been recruited as a group leader at the School of Pharmaceutical Sciences, Chongqing University, and conduct her independent research at the interface of chemistry and biology. Her current research mainly centers around the chemistry and biology of novel drug candidates as well as the supramolecular assemblies with biological activity as drug self-delivery system. She has co-authored more than 40 scientific papers and 4 patents, including J. Med. Chem., Chem. Commun., Org. Lett., Cancer Lett., Chem. Rev., Drug Discov. Today etc., as well as coordinated and participated in more than 10 national and international projects. Dr. XIA has also been appointed as peer reviewer of more than 10 international scientific journals in chemistry, pharmaceutical science and biology, such as New J. Chem., Bioorg. Med. Chem. Lett., Eur. J. Org. Chem., Mol. Pharmaceut. and Cell Proliferat., etc. In 2016, she was awarded as Outstanding Reviewer for New Journal of Chemistry (RSC).

Activities

Collapse all

Chongqing University: Chongqing, Sichuan, CN

2014-09-05 to present | Professor (School of Pharmaceutical Sciences)

Employment

Yi Xia

https://orcid.org/0000-0001-5863-7272

Personal information

Biography

Activities

Employment (4)

Chongqing University: Chongqing, Sichuan, CN

Vancouver Prostate Centre: Vancouver, BC, CA

Centre Interdisciplinaire de Nanoscience de Marseille: Marseille, Provence-Alpes-Côte d'Azu, FR

Centre Interdisciplinaire de Nanoscience de Marseille: Marseille, Provence-Alpes-Côte d'Azu, FR

Education and qualifications (1)

Wuhan University: Wuhan, Hubei, CN

Works (30)

Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function

Negative dendritic effect on enzymatic hydrolysis of dendrimer conjugates.

E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.

Acyclonucleosides bearing coplanar arylethynyltriazole nucleobases: synthesis, structural analysis, and biological evaluation

Microwave promoted C–O coupling for synthesizing O-aryloxytriazole nucleoside analogues

A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor.

Pd-catalyzed oxidative C-H alkenylation for synthesizing arylvinyltriazole nucleosides.

Novel triazole nucleoside inhibits heat shock factor 1 and androgen receptor to fight against prostate cancer

C-S coupling using a mixed-ligand Pd catalyst: a highly effective strategy for synthesizing arylthio-substituted heterocycles.

Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer.

Photoactivatable lipid probes for studying biomembranes by photoaffinity labeling.

A bola-phospholipid bearing tetrafluorophenylazido chromophore as a promising lipid probe for biomembrane photolabeling studies.

A novel bitriazolyl acyclonucleoside endowed with dual antiproliferative and immunomodulatory activity.

Rationalizing the F···S interaction discovered within a tetrafluorophenylazido-containing bola-phospholipid.

An efficient mixed-ligand Pd catalytic system to promote C-N coupling for the synthesis of N-arylaminotriazole nucleosides.

Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer.

Targeting heat shock response pathways to treat pancreatic cancer.

Photoactivatable phospholipids bearing tetrafluorophenylazido chromophores exhibit unprecedented protonation-state-dependent 19F NMR signals.

Bitriazolyl acyclonucleosides synthesized via Huisgen reaction using internal alkynes show antiviral activity against tobacco mosaic virus.

Ligand-mediated highly effective and selective C-N coupling for synthesizing bioactive N-aryltriazole acyclonucleosides.

A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells.

Triazole nucleoside derivatives bearing aryl functionalities on the nucleobases show antiviral and anticancer activity.

S-aryltriazole acyclonucleosides: synthesis and biological evaluation against hepatitis C virus.

N-aryltriazole ribonucleosides with potent antiproliferative activity against drug-resistant pancreatic cancer.

Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer.

Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.

Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication.

Synthesis of bitriazolyl nucleosides and unexpectedly different reactivity of azidotriazole nucleoside isomers in the Huisgen reaction.

Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus.

Photolabeling probes of ribavirin and EICAR.

Peer review (1 review for 1 publication/grant)